Top

European Journal of Nuclear Medicine and Molecular Imaging

Published in:

01-04-2003 | Original Article

Patient dosimetry for ¹³¹I-lipiodol therapy

Authors: Myriam A. Monsieurs, Klaus Bacher, Boudewijn Brans, Anne Vral, Leo De Ridder, Rudi A. Dierckx, Hubert M. Thierens

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 4/2003

Abstract

Patient dosimetry data for intra-arterialiodine-131 lipiodol therapy for hepatocellular carcinoma (HCC) are scarce. The aim of this study was to determine the absorbed dose (D) to the tumour and healthy tissues, as well as the effective dose (E), by different methods for 17 therapies in 15 patients who received a mean activity of 1.9 GBq (SD 0.2) ¹³¹I-lipiodol. Eight patients received thyroid blocking by potassium iodide (KI). Patient dosimetry was performed based on bi-planar total body scans using the Monte Carlo simulation program MCNP-4B and the MIRDOSE-3 standard software program. CT images of each patient were used to determine liver and tumour volume and position. The total body dose to the patient was also determined by biological dosimetry with the in vitro micronucleus (MN) assay. From the increase in micronucleus yield after therapy, the equivalent total body dose (ETBD) was calculated. Results for D and E were comparable between MCNP and MIRDOSE (liver: mean 7.8 Gy, SD 1.8, lungs: 6.8 Gy, SD 2.9, E: 2.01 Gy, SD 0.58). MIRDOSE gave a systematic overestimation for the tumour dose, especially for tumours <3 cm (15%). The MCNP method is more accurate since the dose contributions from tumour to organs and vice versa can be accounted for. The absorbed dose to the thyroid was significantly lower for patients who received KI (7.2 Gy, SD 2.2) than for the other patients (13.8 Gy, SD 5.0). MN yields could be obtained for only 12 of the 17 therapies due to hypersplenism. A mean ETBD of 1.66 Gy (SD 0.73) was obtained, but the MN results showed no correlation between the ETBD and the total body dose values of the physical dosimetry. Also, in all except one of the patients, no further reduction in the number of thrombocytes was observed after therapy, probably due to the existing hypersplenism. It is concluded that in view of the high E values, patient dosimetry is necessary for patients receiving ¹³¹I-lipiodol therapy. Except in the case of the smaller tumours, comparable results were obtained with MCNP and MIRDOSE. Due to hypersplenism, biological dosimetry results based on the MN assay are not reliable.

Novell JR, Hilson AJW. Iodine 131-lipiodol for hepatocellular carcinoma: the benefits of targeting [editorial]. J Nucl Med 1994; 35:1318–1320.

Nakakuma K, Tashiro S, Uemura K, et al. Studies on anticancer treatments with an oily anticancer drug injected into the ligated hepatic artery for hepatic cancer. Nichidoku Iho 1979; 24:675–682.

Ohishi H, Uchida H, Yoshimura H, et al. Hepatocellular carcinoma detected by iodized oil. Use of anticancer agents. Radiology 1985; 154:25–29.

Raoul JL, Guyader D, Bretagne JF, et al. Prospective randomized trial of chemo embolisation versus intra-arterial injection of 131-I-labeled-iodized oil in the treatment of hepatocellular carcinoma. Hepathology 1997; 26:1156–1161.

Lau WY, Leung TWT, Ho SKW, et al. Adjuvant intra-arterial lipiodol iodine 131 for resectable hepatocellular carcinoma: a prospective randomized trial. Lancet 1999; 353:797–801.

Raoul J-L, Bourguet P, Bretagne J-F, et al. Hepatric artery injection of I-131-labeled lipiodol. Part I. Biodistribution study results in patients with hepatocellular carcinoma and liver metastases. Radiology 1988; 168:541–545.

Madsen MT, Park CH, Thakur MI. Dosimetry of iodine-131 ethiodol in the treatment of hepatoma. J Nucl Med 1988; 29:1038–1044.

Nakajo M, Kobayashi H, Shimabukuro K, et al. Biodistribution and in-vivo kinetics of iodine-131-lipiodol infused via the hepatic artery of patients with hepatic cancer. J Nucl Med 1988; 29:1066–1077.

International Commission on Radiation Units. ICRU report 44. Tissue substitutes in radiation dosimetry and measurement. 1989

10.

The International Commission on Radiological Protection. Recommendations of the International Commission on Radiological Protection. ICRP publication 60. Oxford: Pergamon Press, 1990.

11.

Vral A, Verhaegen F, Thierens H, et al. The in-vitro cytokinesis blocked micronucleus assay: a detailed description of an improved slide preparation technique for the automated detection of micronuclei in human lymphocytes. Mutagenesis 1994; 9:439–443.

12.

Fenech M. The cytokinesis blocked micronucleus assay: a detailed description of the method and its application to genotoxicity studies in human populations. Mutat Res 1993; 285:35–44.

13.

Thierens H, Vral A, De Ridder L, et al. Interlaboratory comparison of cytogenetic endpoints for the biomonitoring of radiological workers. Int J Radiat Biol 1999; 75:23–34.

14.

Raoul JL, Bretagne JF, Caucanas JP, et al. Internal radiation therapy for hepatocellular carcinoma. Results of a French multicenter phase II trial of transarterial injection of iodine 131-labeled lipiodol. Cancer 1992; 69:346–352.

15.

European Association of Nuclear Medicine. Monograph: (I-131)-ethiodized oil therapy, Taskgroup Radionuclide Therapy. www.eanmrtc.org/monogrph/lipiodol.htm; 2000.

16.

Toubeu M, Tauzery C, Berriolo-Riedinger A, et al.¹³¹I thyroid uptake in patients treated with ¹³¹I-lipiodol for hepatocellular carcinoma [letter]. Eur J Nucl Med 2001; 28:669–670.

17.

Bacher K, Brans B, Monsieurs M, De Winter F, Dierckx RA, Thierens H. Thyroid uptake and radiation dose after 131I-lipiodol treatment: is thyroid blocking by potassium iodide necessary? Eur J Nucl Med 2002; 29:1311-1316.

18.

Akimaru K, Onda M, Tajiri T, et al. Hypersplenism induced by hepatectomy. Hepatogastroenterology 2001; 48:1170–1175.

19.

Bain BJ. Blood cells a practical guide, 2nd edn. Oxford: Blackwell Scientific, 1995.

20.

United Nations Commission on the Effects of Atomic Radiation (UNSCEAR). Sources and effects of ionizing radiation. Report to the General Assembly, Vienna, Austria, United Nations Commission on the Effects of Atomic Radiation, 1988.

Title: Patient dosimetry for 131I-lipiodol therapy
Authors: Myriam A. Monsieurs
Klaus Bacher
Boudewijn Brans
Anne Vral
Leo De Ridder
Rudi A. Dierckx
Hubert M. Thierens
Publication date: 01-04-2003
Publisher: Springer-Verlag
Published in: European Journal of Nuclear Medicine and Molecular Imaging / Issue 4/2003
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-002-1108-7

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Patient dosimetry for ¹³¹I-lipiodol therapy

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2003

Comparison of methods for thyroid volume estimation in patients with Graves' disease

Quantitative cerebral H2 15O perfusion PET without arterial blood sampling, a method based on washout rate

Respiratory motion artifacts on PET emission images obtained using CT attenuation correction on PET-CT

Extratemporal hypometabolism on FDG PET in temporal lobe epilepsy as a predictor of seizure outcome after temporal lobectomy

99mTcO(BAT-NI), a novel nitroimidazole tracer: in vivo uptake studies in ischaemic myocardium

Accuracy of image fusion of normal upper abdominal organs visualized with PET/CT